A controlled, double-blind study of the effect of Quazolast on nasal challenge with ragweed antigen

N. K. Dave, S. C. McMahon, R. E. Grubbe, Againdra K. Bewtra, R. J. Hopp, N. M. Nair, J. Smith, R. G. Townley

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Quazolast is a potent mediator release inhibitor as determined by in vitro and in vivo testing. A placebo-controlled, double-blind, two-way crossover study compared the safety and efficacy of Quazolast, 400 mg bid orally, with placebo with 23 subjects with ragweed (RW) allergy, out of season. Subjects were assigned to two 7-day treatments in a random sequence with an 8-day washout. Subjects were challenged on days 1 and 7 of each trial with serial dilutions (10, 100, 1000, 1350, and 2700 PNU/0.135 mL) of RW, using metered pump spray bottles, (two sprays delivered 0.135 mL), preceded by saline control. Efficacy evaluation consisted of nasal flow rates measured by rhinomanometry, sneeze counts, nasal itchiness scores, and weight of nasal secretions during challenges. During Quazolast treatment, subjects had significantly lower (P <.05) mean percent decreases in nasal flow rate at 1350 and 2700 PNU. Nasal itchiness scores were significantly lower (P <.05) during Quazolast treatment than placebo at 1000, 1350, and 2700 PNU. Although sneeze counts were lower during treatment with Quazolast than with placebo, the results did not reach statistical significance. No significant improvement was seen in the weight of nasal secretion. Adverse experiences, clinical laboratory results, and physical examinations were unremarkable, posttreatment. Quazolast was superior to placebo in protecting against nasal congestion and nasal itchiness after ragweed nasal challenge.

Original languageEnglish
Pages (from-to)298-302
Number of pages5
JournalAnnals of Allergy
Volume65
Issue number4
StatePublished - 1990

Fingerprint

Ambrosia
Nose
Double-Blind Method
Antigens
Placebos
Rhinomanometry
quazolast
Weights and Measures
Therapeutics
Cross-Over Studies
Physical Examination
Hypersensitivity
Safety

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy

Cite this

Dave, N. K., McMahon, S. C., Grubbe, R. E., Bewtra, A. K., Hopp, R. J., Nair, N. M., ... Townley, R. G. (1990). A controlled, double-blind study of the effect of Quazolast on nasal challenge with ragweed antigen. Annals of Allergy, 65(4), 298-302.

A controlled, double-blind study of the effect of Quazolast on nasal challenge with ragweed antigen. / Dave, N. K.; McMahon, S. C.; Grubbe, R. E.; Bewtra, Againdra K.; Hopp, R. J.; Nair, N. M.; Smith, J.; Townley, R. G.

In: Annals of Allergy, Vol. 65, No. 4, 1990, p. 298-302.

Research output: Contribution to journalArticle

Dave, NK, McMahon, SC, Grubbe, RE, Bewtra, AK, Hopp, RJ, Nair, NM, Smith, J & Townley, RG 1990, 'A controlled, double-blind study of the effect of Quazolast on nasal challenge with ragweed antigen', Annals of Allergy, vol. 65, no. 4, pp. 298-302.
Dave, N. K. ; McMahon, S. C. ; Grubbe, R. E. ; Bewtra, Againdra K. ; Hopp, R. J. ; Nair, N. M. ; Smith, J. ; Townley, R. G. / A controlled, double-blind study of the effect of Quazolast on nasal challenge with ragweed antigen. In: Annals of Allergy. 1990 ; Vol. 65, No. 4. pp. 298-302.
@article{de96ea5f2fee405381b0db085f74a802,
title = "A controlled, double-blind study of the effect of Quazolast on nasal challenge with ragweed antigen",
abstract = "Quazolast is a potent mediator release inhibitor as determined by in vitro and in vivo testing. A placebo-controlled, double-blind, two-way crossover study compared the safety and efficacy of Quazolast, 400 mg bid orally, with placebo with 23 subjects with ragweed (RW) allergy, out of season. Subjects were assigned to two 7-day treatments in a random sequence with an 8-day washout. Subjects were challenged on days 1 and 7 of each trial with serial dilutions (10, 100, 1000, 1350, and 2700 PNU/0.135 mL) of RW, using metered pump spray bottles, (two sprays delivered 0.135 mL), preceded by saline control. Efficacy evaluation consisted of nasal flow rates measured by rhinomanometry, sneeze counts, nasal itchiness scores, and weight of nasal secretions during challenges. During Quazolast treatment, subjects had significantly lower (P <.05) mean percent decreases in nasal flow rate at 1350 and 2700 PNU. Nasal itchiness scores were significantly lower (P <.05) during Quazolast treatment than placebo at 1000, 1350, and 2700 PNU. Although sneeze counts were lower during treatment with Quazolast than with placebo, the results did not reach statistical significance. No significant improvement was seen in the weight of nasal secretion. Adverse experiences, clinical laboratory results, and physical examinations were unremarkable, posttreatment. Quazolast was superior to placebo in protecting against nasal congestion and nasal itchiness after ragweed nasal challenge.",
author = "Dave, {N. K.} and McMahon, {S. C.} and Grubbe, {R. E.} and Bewtra, {Againdra K.} and Hopp, {R. J.} and Nair, {N. M.} and J. Smith and Townley, {R. G.}",
year = "1990",
language = "English",
volume = "65",
pages = "298--302",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "4",

}

TY - JOUR

T1 - A controlled, double-blind study of the effect of Quazolast on nasal challenge with ragweed antigen

AU - Dave, N. K.

AU - McMahon, S. C.

AU - Grubbe, R. E.

AU - Bewtra, Againdra K.

AU - Hopp, R. J.

AU - Nair, N. M.

AU - Smith, J.

AU - Townley, R. G.

PY - 1990

Y1 - 1990

N2 - Quazolast is a potent mediator release inhibitor as determined by in vitro and in vivo testing. A placebo-controlled, double-blind, two-way crossover study compared the safety and efficacy of Quazolast, 400 mg bid orally, with placebo with 23 subjects with ragweed (RW) allergy, out of season. Subjects were assigned to two 7-day treatments in a random sequence with an 8-day washout. Subjects were challenged on days 1 and 7 of each trial with serial dilutions (10, 100, 1000, 1350, and 2700 PNU/0.135 mL) of RW, using metered pump spray bottles, (two sprays delivered 0.135 mL), preceded by saline control. Efficacy evaluation consisted of nasal flow rates measured by rhinomanometry, sneeze counts, nasal itchiness scores, and weight of nasal secretions during challenges. During Quazolast treatment, subjects had significantly lower (P <.05) mean percent decreases in nasal flow rate at 1350 and 2700 PNU. Nasal itchiness scores were significantly lower (P <.05) during Quazolast treatment than placebo at 1000, 1350, and 2700 PNU. Although sneeze counts were lower during treatment with Quazolast than with placebo, the results did not reach statistical significance. No significant improvement was seen in the weight of nasal secretion. Adverse experiences, clinical laboratory results, and physical examinations were unremarkable, posttreatment. Quazolast was superior to placebo in protecting against nasal congestion and nasal itchiness after ragweed nasal challenge.

AB - Quazolast is a potent mediator release inhibitor as determined by in vitro and in vivo testing. A placebo-controlled, double-blind, two-way crossover study compared the safety and efficacy of Quazolast, 400 mg bid orally, with placebo with 23 subjects with ragweed (RW) allergy, out of season. Subjects were assigned to two 7-day treatments in a random sequence with an 8-day washout. Subjects were challenged on days 1 and 7 of each trial with serial dilutions (10, 100, 1000, 1350, and 2700 PNU/0.135 mL) of RW, using metered pump spray bottles, (two sprays delivered 0.135 mL), preceded by saline control. Efficacy evaluation consisted of nasal flow rates measured by rhinomanometry, sneeze counts, nasal itchiness scores, and weight of nasal secretions during challenges. During Quazolast treatment, subjects had significantly lower (P <.05) mean percent decreases in nasal flow rate at 1350 and 2700 PNU. Nasal itchiness scores were significantly lower (P <.05) during Quazolast treatment than placebo at 1000, 1350, and 2700 PNU. Although sneeze counts were lower during treatment with Quazolast than with placebo, the results did not reach statistical significance. No significant improvement was seen in the weight of nasal secretion. Adverse experiences, clinical laboratory results, and physical examinations were unremarkable, posttreatment. Quazolast was superior to placebo in protecting against nasal congestion and nasal itchiness after ragweed nasal challenge.

UR - http://www.scopus.com/inward/record.url?scp=0025131160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025131160&partnerID=8YFLogxK

M3 - Article

C2 - 2221488

AN - SCOPUS:0025131160

VL - 65

SP - 298

EP - 302

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 4

ER -